Treatment, prognostic factors, and outcomes in spinal cord astrocytomas

63Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Spinal astrocytomas are rare intramedullary CNS tumors for which there is limited consensus on treatment; the importance of the extent of resection (EOR), postoperative radiotherapy, and chemotherapy remains poorly understood. We report on outcomes associated with surgery, postoperative radiotherapy, and chemotherapy in a series of patients treated at M. D. Anderson Cancer Center (MDACC) with the aim of elucidating the role of these treatments in spinal astrocytomas. Methods. We retrospectively reviewed charts from a series of 83 patients with histologically confirmed spinal astrocytoma treated at MDACC during 1990- 2011. Data collected included patient demographic characteristics, prognostic indicators, and treatment modality at diagnosis. We analyzed overall survival (OS) and progression-free survival (PFS) for pilocytic (World Health Organization [WHO] grade I) and infiltrative (WHO grades II, III, and IV) astrocytomas, separately. Multivariate analysis was performed for the infiltrative patients but not the pilocytic patients because of a limited number of cases. Results. Higher WHO grade among all patients was associated with worse OS (P

Cite

CITATION STYLE

APA

Fakhreddine, M. H., Mahajan, A., Penas-Prado, M., Weinberg, J., McCutcheon, I. E., Puduvalli, V., & Brown, P. D. (2013, April). Treatment, prognostic factors, and outcomes in spinal cord astrocytomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/nos309

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free